Firm targets Siemens installed base The aging installed base of nuclear medicine gamma cameras representsa profitable niche for some companies that have made a businessout of keeping older cameras current. One such firm, MIE Americaof Elk Grove
The aging installed base of nuclear medicine gamma cameras representsa profitable niche for some companies that have made a businessout of keeping older cameras current. One such firm, MIE Americaof Elk Grove Village, IL, is targeting legacy gamma cameras withits Scintron IV product, an acquisition and processing computerdesigned as a replacement for consoles still in use on equipment15 to 20 years old.
MIE America is the U.S. subsidiary of Medical Imaging Electronics,a German company that has been refurbishing gamma cameras in Europefor the past 15 years. MIE's U.S. unit debuted Scintron IV atthe Society of Nuclear Medicine meeting in June and submitteda 510(k) application for the product in the same month.
MIE has been selling the data acquisition and processing computerin Europe for the last three years. It opened a U.S. branch nearChicago last year, where staff are remanufacturing Siemens andGE gamma cameras. John Loebel, product manager for Scintron IV,said the computer has been installed and is operating at morethan 130 European university and private sites.
MIE America will sell Scintron IV as part of gamma camerasit remanufactures and as replacement consoles to the installedbase of obsolete nuclear medicine computer technology.
Initially, the Scintron IV will replace the Siemens DOT (digitaloperators terminal) and Siemens Scintiview consoles.
"Those are aging pieces of equipment, some more than 20years old," Loebel said.
MIE is expanding Scintron IV to interface with any of the othergamma cameras that may be in need of an updated computer system.
The company's primary competitor will be Medasys Digital Systemsof Atlanta, a gamma camera refurbisher and workstation vendorthat markets the Pinnacle series of computers. Many of MIE America'sstaff are ex-Medasys employees, Loebel noted.
MIE is bucking the trend toward off-the-shelf computers torun custom software, preferring to make use of proprietary architecturefor Scintron IV, which features Motorola 68000 series chips anda VME bus. The computer runs on an OS/9 operating system developedby Microware Systems in Des Moines.
Loebel said the custom-built computer is needed to get thehigh-speed parallel processing necessary in a multi-user/multi-taskingenvironment, characterized by simultaneous data acquisition, processingand image printing.
"The performance outweighs the additional costs of speciallymaking the computers," Loebel said.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.